Thera-GAM

The Problem

• Genetic variation in non-coding regulatory regions accounts for up to 90% of heritability in neurological disorders, many with poor prognoses and treatment outcomes.
• For example, pediatric cancers (e.g. neuroblastoma, glioma) have < 50% survival rates and account for over 20% of cancer deaths.
• Cancer cells can rewire non-coding regulatory enhancer usage and long‑range genomic interactions to activate oncogenes.
• Direct gene targeting is not possible, and current approaches fail to capture targets of regulatory regions.
• There is a critical unmet need for approaches which combine clinical, genomic and 3D genome structure profiles to connect genetics with molecular mechanisms of disease.

The Solution

• Thera-GAM uses Genome Architecture Mapping (GAM) to profile 3D genome structure in single cells directly from patient samples.
• GAM captures spatial interactions between genomic variants and target genes in complex diseases (e.g. cancer, epilepsy).
• Highly scalable with all experimental steps automated, enabling rapid collection of large datasets at low cost.
• Novel non-coding target discovery direct from patient-derived samples.
• Clinical profiling of key physical genomic interactions.
• First-in-class therapeutic discovery in glioma and neuroblastoma.

Looking for

• Investors for pre-seed validation
• Co-development opportunities
• Industry partners

Technology

Thera-GAM is also available as technology asset.

News and background